Apalutamide in the treatment of non-metastatic castration-resistant prostate cancer in an elderly patient with multiple comorbidities

نویسندگان

چکیده

Prostate cancer has been the most common malignant tumor in men Poland since 2016 and is second cause of death this group patients. The basic method treatment patients with advanced prostate androgen deprivation therapy, however, over time, evolves into a castration-resistant form, which poses significant threat to patient's life. This article presents case an elderly patient internal diseases, who stage, was treated new generation receptor blocker – apalutamide first line systemic treatment.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.

Prostate cancer is initially responsive to androgen deprivation therapy, but most patients eventually develop castration-resistant disease. Enzalutamide is an androgen receptor (AR) inhibitor that targets several steps in the AR signaling pathway and has shown significant efficacy in the treatment of metastatic castration-resistant prostate cancer in patients with or without prior chemotherapy....

متن کامل

The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with co...

متن کامل

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutionized the treatment of CRPC but has also raised the question of what is the ideal sequence of admin...

متن کامل

Single Orbital Metastasis in Castration-Resistant Prostate Cancer

Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: OncoReview

سال: 2023

ISSN: ['2082-8691']

DOI: https://doi.org/10.24292/01.or.131300323